CSL stock analysis
CSL (CMXHF) Stock Price & Analysis
CMXHF Stock Chart & Stats
- Day’s Range
- $126.11 - $132.38
- 52-Week Range
- $63.84 - $146.48
- Previous Close
- $133.82
- Volume
- N/A
- Average Volume (3M)
- 222
- Market Cap
- $63.89B
- Enterprise Value
- $70.67B
- Total Cash (Recent Filing)
- $1.51B
- Total Debt (Recent Filing)
- $10.89B
- Price to Earnings (P/E)
- ―
- Beta
- -0.01
- Next Earnings
- Feb 09, 2027 (Est.)
- Last Dividend Ex-Date
- Sep 10, 2026
- Dividend Yield
- 2.18%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Positive operating cash flow despite a reported net loss demonstrates that CSL’s core operations continue to generate funds. This supports investment, dividends and buybacks while providing financial flexibility to manage restructuring, capital spending and portfolio remediation over the next several quarters.
Transformation Savings
The transformation program is producing measurable savings ahead of its initial target, with further benefits planned over the next two years. If execution continues, lower operating costs can support margins, fund commercial and R&D reinvestment, and improve earnings quality without relying solely on revenue growth.
Product And Franchise Momentum
Growth from newly launched and specialty products strengthens CSL’s product portfolio beyond mature therapies. ANDEMBRY, HEMGENIX and immunoglobulin momentum can support durable revenue expansion, improve mix and partially offset pressure in weaker franchises as adoption broadens across markets.
Bears Say
Large Impairments And Loss
The scale of impairments and the statutory loss materially weaken recent earnings quality and reduce confidence in the carrying value of acquired assets. Although impairments are non-cash, they signal portfolio underperformance and may constrain management’s flexibility while remediation and restructuring continue.
Structural Vifor Decline
Vifor faces several durable commercial and regulatory pressures rather than a temporary demand fluctuation. Generic competition, lost reimbursement support and the TAVNEOS authorization issue can reduce revenue and earnings, leaving the group more dependent on Behring and successful replacement products.
Albumin Pressure In China
The decline in albumin reflects persistent pricing and market-value pressure in an important geography, not simply a one-period volume disruption. Continued pressure can weigh on Behring’s product mix and gross margin, limiting the benefit of growth in immunoglobulins and newer therapies.
CSL News
CMXHF FAQ
What was CSL’s price range in the past 12 months?
What is CSL’s market cap?
When is CSL’s upcoming earnings report date?
How were CSL’s earnings last quarter?
Is CSL overvalued?
Does CSL pay dividends?
What is CSL’s EPS estimate?
How many shares outstanding does CSL have?
What happened to CSL’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CSL?
What is the TipRanks Smart Score and how is it calculated?
CSL Stock Smart Score
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gordon Naylor DipCompSc
- Employees
- 29,000
- Website
- www.csl.com
- Address
- 655 Elizabeth Street, Melbourne, VIC, 3000, AU
CSL (CMXHF) Earnings & Revenues
CMXHF Company Deck
CMXHF Earnings Call
Earnings Call SentimentNegative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.
View all CMXHF earnings summariesCMXHF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |










